FindTrial
Sign In

Camrelizumab plus Apatinib

DRUG6 trials

Sponsors

Zhejiang University, Peking University, Henan Cancer Hospital, Wan-Guang Zhang, Peking University Cancer Hospital & Institute

Conditions

Gastric CancerHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Liver Cancer AdultLiver TransplantMacrotrabecular Massive Hepatocellular CarcinomaSmall Cell Lung CarcinomaUnresectable Hepatocellular Carcinoma

Phase 1

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
NCT04035876
Zhejiang UniversityHepatocellular Carcinoma, Liver Transplant
Start: 2019-07-16End: 2021-12-31Target: 120Updated: 2019-07-29

Phase 2

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT04609176
Peking UniversityGastric Cancer
Start: 2020-11-18End: 2024-12-31Target: 64Updated: 2023-04-21
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
NCT04901754
Henan Cancer HospitalSmall Cell Lung Carcinoma
Start: 2021-07-14End: 2023-03-31Target: 38Updated: 2021-12-08
A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
NCT05839197
Wan-Guang ZhangMacrotrabecular Massive Hepatocellular Carcinoma
Start: 2023-05-05End: 2025-04-15Target: 38Updated: 2023-12-19
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
RecruitingNCT06360042
Peking University Cancer Hospital & InstituteUnresectable Hepatocellular Carcinoma
Start: 2024-01-01End: 2028-03-31Target: 111Updated: 2024-04-22
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
Not yet recruitingNCT07314372
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHepatocellular Carcinoma (HCC), Liver Cancer Adult, Unresectable Hepatocellular Carcinoma (HCC)
Start: 2026-02-01End: 2028-12-01Target: 86Updated: 2026-01-20

Related Papers

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
2025-03-149 citations
Effect of AFPGC immune-microenvironment and resistance to immunotherapy.
Journal of Clinical Oncology2024-06-011 citations
Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
Journal of Clinical Oncology2024-01-204 citations
Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial
OncoTargets and Therapy2021-09-015 citations